October 2023 - Page 13 of 16

Dr. Huaqing Wang: Primary Mediastinal B-Cell Lymphoma (PMBCL) Benefits More Significantly from Axi-Cel Treatment

By Peter W. PENG 2023.10.12

From June 8th to 11th, 2023, the 28th European Hematology Association Congress (EHA) will take place in Frankfurt, Germany, in both online and offline formats, organized by the European Hematology Society. As the largest international conference in the field of European hematology, the EHA Congress will cover various scientific topics, clinical and basic research, benign and malignant hematology, and discuss the latest developments in the field of hematology.

Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

By Peter W. PENG 2023.10.12

From June 8 to 12, 2023, the 28th European Hematology Association (EHA) Congress will be held in Frankfurt, Germany, bringing together experts and scholars from around the world to present exciting advances in research. In the field of hematology testing, multi-parameter flow cytometry (MFC) is an important clinical diagnostic method, and the development of fast, simple, and efficient protocols is essential for this technology. A real-world study (P588) conducted by Dr. Hui Wang's team from Hebei Yanda Ludaopei Hospital and Beijing Ludaopei Hospital has been selected for presentation at EHA.

Dr. Daobin Zhou’s Team: Zanubrutinib combined with R-CHOP regimen demonstrates efficacy and safety in primary treatment of Intravascular Large B-Cell Lymphoma

By Peter W. PENG 2023.10.12

Intravascular Large B-Cell Lymphoma (IVLBCL) is a subtype of large B-cell lymphoma, characterized by large tumor B-cells aggregating inside blood vessels. This disease is extremely rare and highly malignant, often involving the central nervous system, lungs, and skin. Its prognosis is poor and clinical treatment challenging. At the recently concluded 28th European Hematology Association (EHA) Annual Meeting, a study (Abstract Number: P1185) from Dr. Daobin Zhou's team at Peking Union Medical College Hospital was selected. This study evaluated the efficacy and safety of the Zanubrutinib combined with R-CHOP regimen in treating initial IVLBCL, attracting widespread attention. To further understand this study, the Oncolgy Fronter invited Dr. Zhou for a detailed interpretation and analysis, summarized as follows:

Dr. Xiaoting Hua: Groundbreaking Findings on Cefiderocol Resistance in Acinetobacter baumannii 丨ECCMID 2023

By Peter W. PENG 2023.10.12

At the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) held in Copenhagen, Dr. Xiaoting Hua of the Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine unveiled significant findings. His research focused on mutations that mediate Acinetobacter baumannii's resistance and virulence to a new antibiotic, Cefiderocol.

Dr. Yimin Wang: Advances in Ventilator-Associated Pneumonia Research丨ECCMID 2023

By Peter W. PENG 2023.10.12

Ventilator-Associated Pneumonia (VAP) continues to be a critical concern in intensive care units, leading to prolonged hospital stays and increased mortality rates. The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2023 unveiled crucial research findings shedding light on innovative approaches to VAP diagnosis and treatment. In this article, we present a synthesis of the key discoveries from ECCMID 2023, offering insights into the evolving landscape of VAP research.

Interview with Chao Zhuo at ECCMID 2023

By Peter W. PENG 2023.10.12

The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) took place in Copenhagen, Denmark, from April 15th to 18th, 2023. As one of the most significant conferences in the field of clinical microbiology and infectious diseases, it marked a significant gathering after a three-year hiatus due to the pandemic. Chinese experts, including Dr. Chao Zhuo from The First Affiliated Hospital of Guangzhou Medical University, were present to share their insights.

Dr. Graham Taylor: Understanding and Combatting HTLV-1丨ECCMID 2023

By Peter W. PENG 2023.10.12

HTLV-1, a retrovirus closely associated with certain forms of cancer, remains a lesser-known but significant global health concern. Despite its considerable impact on populations around the world, there is a lack of attention and understanding regarding this infection. This article sheds light on the challenges posed by HTLV-1 and emphasizes the need for increased awareness, research, and interventions.

Antimicrobial Susceptibility Testing: The Joint Efforts of CLSI and EUCAST丨ECCMID 2023

By Peter W. PENG 2023.10.12

Antimicrobial susceptibility testing (AST) is pivotal in both individualized and empirical treatments. Notably, standards set for interpreting AST results enable clinicians to choose suitable medications and optimal treatment plans, acting as a significant tool in controlling antimicrobial resistance. The most influential bodies in this space are the Clinical and Laboratory Standards Institute (CLSI) of the United States and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). These entities aim to standardize AST procedures and reduce experimental errors.

Dr. Biao Zhu: Common Comorbidities in HIV Patients and Their Antiretroviral Therapy

By Peter W. PENG 2023.10.12

Although antiretroviral therapy (ART) has greatly reduced the mortality associated with HIV, the morbidity of non-AIDS-related complications associated with HIV remains high. Therefore, it is crucial to understand and assess clinical decision factors for adjusting ART in the context of suppressed HIV RNA. At the recently concluded 12th International AIDS Society HIV Science Conference ( IAS 2023), Dr. A. Cozzi-Lepri of University College London reported a study (Abstract number: EPB0169) that analyzed and evaluated the risk of ART switches in the context of common comorbidities combined with HIV and suppressed HIV RNA. This journal specially invited Dr. Biao Zhu from the First Affiliated Hospital of Zhejiang University School of Medicine, China, to provide a brilliant review of this research.

Dr. Hui Wang: Second-line treatment choice for children with HIV infection

By Peter W. PENG 2023.10.12

Currently, the choice of second-line antiretroviral therapy (ART) for children infected with HIV is extremely limited. At the12th International AIDS Society HIV Science Conference (IAS 2023), researchers announced the results of a significant clinical study, the CHAPAS-4 ( Abstract No. OALBB0503), focusing on the long-term treatment outcomes of second-line therapy in children with HIV infections. We specially invited Dr. Hui Wang from the Affiliated Second Hospital of Southern University of Science and Technology, China, to provide a brilliant review of this research.